双特异性抗体药物特性及其在肺癌治疗中的临床应用  

Characteristics of Bispecific Antibodies and Their Clinical Application in Therapy of Lung Cancer

作　　者：刘思阳 周清 李扬秋[1] 吴一龙 LIU Si-yang Maggie;ZHOU Qing;LI Yang-qiu;WU Yi-long(Department of Hematology,First Affiliated Hospital,Institute of Hematology,School of Medicine,Key Laboratory for Regenerative Medicine of Ministry of Education,Ji'nan University,Guangzhou 510632,China;Guangdong Lung Cancer Institute,Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China)

机构地区：[1]暨南大学附属第一医院血液科,暨南大学医学院血液研究所,暨南大学教育部再生医学重点实验室,广州510632 [2]广东省肺癌研究所,南方医科大学附属广东省人民医院(广东省医学科学院),广州510080

出　　处：《循证医学》2022年第4期243-253,256,共12页The Journal of Evidence-Based Medicine

基　　金：中国博士后基金项目(2021M701422);广东省肺癌转化医学重点实验室(2017B030314120);广东省医学领军人才配套科研项目(KJ012019426);广东省人民医院(广东省医学科学院)“登峰计划:高水平医院建设项目”科研专项(DFJH201810)。

摘　　要：双特异性抗体具有两种不同抗原结合位点,可结合两个不同抗原或同一抗原的两个不同抗原表位,相较于常见的单特异性抗体,双特异性抗体具有提升抗肿瘤效果、不良反应小和抗体用量少的特点。肺癌是双特异性抗体研究重点关注的疾病领域之一,amivantamab的出现和获批上市为患者提供了新的选择。本文对肿瘤治疗领域的双特异性抗体药物特性和肺癌领域双特异性抗体研究进展进行综述,为肺癌的临床治疗提供新思路。Bispecific antibody refers to an antibody that can bind to different types of antigens or two different epitopes on the same antigen.Therefore,compared to monospecific antibodies,bispecific antibodies are characterized by enhanced anti⁃tumor effects,low adverse effects and low antibody dosage.Lung cancer is one of the main study populations for bispecific antibodies,and the advent and approval of amivantamab to market provides a new option for the treatment of lung cancer patients.This paper reviewed the characteristics of bispecific antibodies in tumor therapy and the research progress of bispecific antibodies in lung cancer,so as to provide some new ideas for the clinical treatment of lung cancer.

关 键 词：双特异性抗体 靶向治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]